DexCom vs Labcorp Holdings

DexCom (DXCM), health care, and Labcorp Holdings (LH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

DexCom is worth $30.6B on the stock market and Labcorp Holdings $29.9B: DexCom is valued at 2% more. DexCom trades at 32.2 times earnings and Labcorp Holdings at 30.5; operating margins in their latest fiscal years were 19.6% and 9.92%. Over the past year DexCom's share price has moved +35.6% and Labcorp Holdings's +43.4%.

Key facts

DexCom market value
$30.6B
Labcorp Holdings market value
$29.9B
DexCom P/E
32.2
Labcorp Holdings P/E
30.5
DexCom revenue
$4.7BFY to 2025-12-31
Labcorp Holdings revenue
$14BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

DexCom vs Labcorp Holdings: every measure side by side
Measure DexCom Labcorp Holdings
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$30.6Bhigher$29.9Blower
Revenue$4.7Blower$14Bhigher
Earnings$836.3Mlower$876.5Mhigher
Employees11,000lower71,000higher
Total assets$6.3Blower$18.4Bhigher
Valuation
P/E32.2higher30.5lower
P/S6.6higher2.1lower
P/B12.1higher3.4lower
Dividend yield0.00%lower0.77%higher
Profitability
Operating margin19.6%higher9.92%lower
Balance sheet
Net assets$2.7Blower$8.6Bhigher
Total liabilities$3.6Blower$9.8Bhigher
Total debt—$5.6B
Cash on hand$917.7Mhigher$532.3Mlower
Price change
Today+0.53%higher-1.13%lower
1 year+35.6%lower+43.4%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. Who owns DXCM · Who owns LH

Further comparisons

Learn

Questions and answers

Which is bigger, DexCom or Labcorp Holdings?

By market value, DexCom is the larger: $30.6B against $29.9B for Labcorp Holdings. By revenue in its latest fiscal year, Labcorp Holdings is the larger: $14B against $4.7B for DexCom.

Which has the higher P/E ratio?

DexCom: 32.2, against 30.5 for Labcorp Holdings. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

DexCom: 19.6%, against 9.92% for Labcorp Holdings. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Labcorp Holdings: 0.77%, against 0.00% for DexCom. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both DexCom and Labcorp Holdings?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold DexCom and 7 hold Labcorp Holdings.

Cite this page

Funkfolio, “DexCom vs Labcorp Holdings”, data as of 18 November 2026. https://funkfolio.com/compare/dxcm-vs-lh

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.